Bimekizumab-bkzx
Cold Chain RequiredFDA Approved
Contents
Description
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines driving inflammatory processes. It is used to treat plaque psoriasis.
Indications & Therapeutic Use
Plaque Psoriasis
Linked Diseases:
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Bimekizumab-bkzx — GNH India
14 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Bimekizumab-bkzx products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Bimekizumab-bkzx
| Generic Name | Bimekizumab-bkzx |
| Brands | 1 brand available |
| Active Ingredient | Bimekizumab |
| Drug Class | Plaque Psoriasis |
| Manufacturer | UCB S.A. |
| Dosage Forms | Subcutaneous injection |
| Medical Code | L04AC18 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03564418 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes